Impact News +++ WDH: Ryanair wagt wegen Iran-Krieg keine Gewinnprognose (DPA-AFX) +++ RYANAIR Aktie -3,35%

KODIAK SCIENCES Aktie

>KODIAK SCIENCES Aktienkurs

30.8 EUR -3.3% (TradegateBSX)

Ask: 30.99 EUR / 155 Stück

Bid: 30.2 EUR / 160 Stück

Tagesumsatz: 1737 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>KODIAK SCIENCES Performance

1 Woche: -12,6%

1 Monat: -14,5%

3 Monate: +67,1%

6 Monate: +79,7%

1 Jahr: +945,1%

laufendes Jahr: +24,2%

>KODIAK SCIENCES Aktie

Name:

KODIAK SCIENCES DL-,0001

Land:

USA

Sektor:

Gesundheit

ISIN/ Wkn:

US50015M1099 / A2N6P0

Symbol/ Ticker:

K27 (Frankfurt) / KOD (NASDAQ)

Kürzel:

FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD

Index:

Webseite:

https://kodiak.com/

Profil:

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on the research, development, and commercialization of novel therapeutics for retinal diseases. The company specializes in next-generation therapies targeting chronic, high-pr..
>Volltext..

Marktkapitalisierung:

1992.72 Mio. EUR

Unternehmenswert:

1980.96 Mio. EUR

Umsatz:

EBITDA:

-179.91 Mio. EUR

Nettogewinn:

-198.41 Mio. EUR

Gewinn je Aktie:

-3.59 EUR

Schulden:

134.18 Mio. EUR

Liquide Mittel:

145.82 Mio. EUR

Operativer Cashflow:

Bargeldquote:

3.42

Umsatzwachstum:

Gewinnwachstum:

-13.3%

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

KODIAK SCIENCES

Letzte Datenerhebung:

18.05.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 62.58 Mio. St.

Frei handelbar: 92.46%

Leerverk. Aktien: 16.38%

Rückkaufquote: -7.72%

Mitarbeiter: 124

Umsatz/Mitarb.: -

Analysten:

Analystenrating: Strong buy

Kursziel: 59.05%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: 21.42

PEG-Ratio: -0.68

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -76.39%

Eigenkaprendite: -208.8%

>Peer Group

Gesundheit, Antikörper- Behandlung, Augenmedizin

>KODIAK SCIENCES Chart & Kurs - NASDAQ

>KODIAK SCIENCES News

17.05.26 - 22:24	Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally (Fool)
	This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials....

07.05.26 - 23:21	Kodiak Sciences GAAP EPS of -$0.94 beats by $0.07 (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

07.05.26 - 22:03	Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results (PR Newswire)
	PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key......

01.05.26 - 06:27	Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences (PR Newswire)
	Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE......

05.04.26 - 01:01	Insiderhandel: Chief Financial Officer verkauft Aktien von Kodiak Sciences im Wert von 1197488 USD (Insiderkauf)
	Borgeson, John A. - Vorstand - Tag der Transaktion: 2026-04-02...

31.03.26 - 22:54	Kodiak Sciences GAAP EPS of -$1.04 in-line (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

31.03.26 - 22:48	Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
	PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3......

27.03.26 - 18:45	KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate (Zacks)
	Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients....

27.03.26 - 03:18	Meta, Kodiak Sciences, Unity Software, Lumentum Holdings And Reddit: Why These 5 Stocks Are On Investors′ Radars Today (Benzinga)
	Major U.S. indices closed lower, with the Dow Jones Industrial Average declining 1.01% to 45,960.11. Importance Rank: 1 read more...

26.03.26 - 15:45	Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday (Benzinga)
	Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc. Importance Rank: 1 read more...

26.03.26 - 13:30	Jefferies Financial, MillerKnoll dip premarket; Kodiak Sciences surges (Investing.com)
	Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.03.26 - 12:18	Kodiak Sciences: Aktie legt nach positiven Studienergebnissen kräftig zu (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

26.03.26 - 11:03	Kodiak Sciences Announces Positive Topline Results in GLOW2, the Second Phase 3 Study in Diabetic Retinopathy, Demonstrating Superiority of Zenkuda™ (tarcocimab tedromer) Over Sham (PR Newswire)
	Building on the success of GLOW1 and with all patients on a 6-month dosing interval, Zenkuda (tarcocimab tedromer) demonstrated superiority to sham with 62.5% of Zenkuda-treated patients achieving a ≥2-step improvement in diabetic retinopathy severity score (DRSS) compared to 3.3% of......

23.02.26 - 20:12	Kodiak Sciences Stock Up 480% as One Fund Discloses $53 Million Buy (Fool)
	Focused on retinal disease therapeutics, this clinical-stage biotech advances drug candidates for vision-threatening conditions....

19.02.26 - 23:48	Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead (Fool)
	Focused on retinal disease therapies, Kodiak Sciences leads with clinical-stage candidates targeting major unmet needs in ophthalmology....

06.02.26 - 19:00	KOD Stock Up 24% in 3 Months: Here′s What You Need to Know (Zacks)
	Kodiak Sciences' shares jump 24% in three months as late-stage retinal programs advance and fresh funding extends its cash runway, fueling investor confidence....

04.02.26 - 13:03	Final APEX Phase 1b Clinical Results for Kodiak′s KSI-101 in Macular Edema Secondary to Inflammation to be Presented at Angiogenesis 2026 (PR Newswire)
	PALO ALTO, Calif., Feb. 4, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today participation at the virtual Angiogenesis......

08.01.26 - 02:21	Kodiak Sciences to Present at 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
	PALO ALTO, Calif., Jan. 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present at the 44th......

20.12.25 - 03:01	Insiderhandel: Aufsichtsrat kauft Aktien von Kodiak Sciences im Wert von 60000008 USD (Insiderkauf)
	Baker Bros. Advisors Lp - Aufsichtsrat - Tag der Transaktion: 2025-12-18...

19.12.25 - 02:30	Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters′ Option to Purchase Additional Shares (PR Newswire)
	PALO ALTO, Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wenn die Leidenschaft oft kühner rät als die Reflexion, so verleiht sie auch mehr Kraft zur Ausführung. - Luc de Clapiers Vauvenargues

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram